Matinas BioPharma Holdings Inc

Matinas BioPharma faces NYSE compliance risks amid quarterly losses; learn how a $0.55 share price and weak earnings threaten its market status.

Matinas BioPharma Holdings’ stock price has declined significantly, with a current value of $0.64 USD, raising concerns about the company’s financial health and future prospects, despite its commitment to advancing biopharmaceutical innovations.